| DB ID | MyCo_6994 |
| Title | Comparable Serum and Plasma 1,3-β-d-Glucan Values Obtained Using the Wako β-Glucan Test in Patients with Probable or Proven Fungal Diseases |
| Year | 2019 |
| PMID | 30842228 |
| Fungal Diseases involved | Candidemia |
| Disease | Candidiasis (Candida Infection) |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | spp. |
| Organism | Candida spp. |
| Ethical Statement | None |
| Site of Infection | Unspecified |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Italy |
| Cohort | Here tested one or more pairs of serum and plasma samples (n=50) from patients with candidiasis (n=10), aspergillosis (n=5), and pneumocystosis (n=3) |
| Cohort No. | 18 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Sub Technique | ELISA |
| Technique | Immunoassay |
| Analysis Method | Wako BDG Assay |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | Wako BDG Assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
